Sanofi Total Current Liabilities 2010-2024 | SNY
Sanofi total current liabilities from 2010 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
- Sanofi total current liabilities for the quarter ending June 30, 2024 were $32.336B, a 19.77% increase year-over-year.
- Sanofi total current liabilities for 2023 were $26.185B, a 3.71% increase from 2022.
- Sanofi total current liabilities for 2022 were $25.248B, a 0.22% increase from 2021.
- Sanofi total current liabilities for 2021 were $25.194B, a 14.59% increase from 2020.
Sanofi Annual Total Current Liabilities
(Millions of US $) |
| 2023 |
$26,185 |
| 2022 |
$25,248 |
| 2021 |
$25,194 |
| 2020 |
$21,987 |
| 2019 |
$22,827 |
| 2018 |
$20,521 |
| 2017 |
$17,471 |
| 2016 |
$18,186 |
| 2015 |
$18,682 |
| 2014 |
$17,323 |
| 2013 |
$18,539 |
| 2012 |
$17,825 |
| 2011 |
$18,920 |
| 2010 |
$15,615 |
| 2009 |
$17,290 |
Sanofi Quarterly Total Current Liabilities
(Millions of US $) |
| 2024-06-30 |
$32,336 |
| 2024-03-31 |
|
| 2023-12-31 |
$26,185 |
| 2023-09-30 |
|
| 2023-06-30 |
$26,998 |
| 2023-03-31 |
|
| 2022-12-31 |
$25,248 |
| 2022-09-30 |
|
| 2022-06-30 |
$23,476 |
| 2022-03-31 |
|
| 2021-09-30 |
|
| 2021-03-31 |
|
| 2020-09-30 |
|
| 2020-03-31 |
|
| 2019-09-30 |
|
| 2019-03-31 |
|
| 2018-03-31 |
|
| 2017-12-31 |
$17,471 |
| 2017-09-30 |
|
| 2017-06-30 |
$18,764 |
| 2017-03-31 |
|
| 2016-12-31 |
$18,186 |
| 2016-09-30 |
|
| 2016-06-30 |
$17,220 |
| 2016-03-31 |
|
| 2015-09-30 |
|
| 2015-06-30 |
$18,026 |
| 2014-06-30 |
$19,480 |
| 2013-06-30 |
$17,798 |
| 2012-06-30 |
$20,657 |
| 2012-03-31 |
|
| 2011-12-31 |
$18,920 |
| 2011-09-30 |
|
| 2011-06-30 |
$23,097 |
| 2011-03-31 |
|
| 2010-12-31 |
$15,615 |
| 2010-09-30 |
|
| 2010-06-30 |
$15,401 |
| 2010-03-31 |
|
| 2009-12-31 |
$17,290 |
| 2009-09-30 |
|
| 2009-06-30 |
$14,693 |
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$145.556B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
